NEW YORK and LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, presented results from the CASCADE and CORONET studies in patients with COVID-19 pneumonia at the American Thoracic Society (ATS) 2022 Annual Meeting.
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here